PharmEasy Secures $216M Funding Led by Manipal Group Amid Valuation Decline.
Expert Analysis:
Funding Infusion Led by MEMG: PharmEasy secures Rs 1,804 crore ($216 million) funding led by Ranjan Pai’s MEMG, indicating investor confidence.
Significant Valuation Decline: The valuation experienced a sharp decline of approximately 90%, now standing at $710 million.
Funding Breakdown: Valuation drops sharply from $5.6 billion in 2021; MEMG’s family office leads with Rs 800 crore, backed by Prosus, Temasek, and 360 One Portfolios with Rs 221 crore, Rs 183 crore, and Rs 200 crore, respectively. Also, CDPQ Private Equity, WSSS Investments, Goldman Sachs, and Evolution Debt Capital invested Rs 400 crore collectively.
Debt Settlement Efforts: Efforts are underway to raise Rs 3,500 crore to settle debts incurred from defaulting on Goldman Sachs' loan terms.
Valuation Reduction History: Valuation was previously reduced by 50% by Janus Henderson and further by 21.4 percent to $4.4 billion as of February 2023 by Neuberger Berman.
